Related Experiment Video
Updated: Apr 4, 2026

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
Published on: May 6, 2014
Therapeutic strategies in pneumonia: going beyond antibiotics
Holger Müller-Redetzky1, Jasmin Lienau1, Norbert Suttorp1
1Dept of Infectious Diseases and Pulmonary Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Abstract:
Dysregulation of the innate immune system drives lung injury and its systemic sequelae due to breakdown of vascular barrier function, harmful hyperinflammation and microcirculatory failure, which contribute to the unfavourable outcome of patients with severe pneumonia. A variety of promising therapeutic targets have been identified and numerous innovative therapeutic approaches demonstrated to improve lung injury in experimental preclinical studies. However, at present specific preventive or curative strategies for the treatment of lung failure in pneumonia in addition to antibiotics are still missing. The aim of this mini-review is to give a short overview of some, but not all, adjuvant therapeutic strategies for pneumonia and its most important complications, sepsis and acute respiratory distress syndrome, and briefly discuss future perspectives.
Insights
Severe pneumonia causes lung injury via immune dysregulation. While preclinical studies show promise, effective treatments beyond antibiotics for pneumonia-induced lung failure, sepsis, and acute respiratory distress syndrome are still needed.
Area of Science:
- Immunology
- Pulmonology
- Critical Care Medicine
Background:
- Innate immune system dysregulation contributes to lung injury in severe pneumonia.
- Breakdown of vascular barrier function, hyperinflammation, and microcirculatory failure worsen patient outcomes.
- Current treatments for pneumonia-induced lung failure, sepsis, and ARDS are limited.
Purpose of the Study:
- To review adjuvant therapeutic strategies for pneumonia and its complications.
- To discuss future perspectives in treating lung failure associated with pneumonia.
Main Methods:
- Mini-review of preclinical and experimental studies.
- Focus on adjuvant therapies beyond antibiotics.
- Discussion of sepsis and acute respiratory distress syndrome (ARDS) as complications.
Main Results:
- Numerous therapeutic targets and approaches show promise in preclinical models.
- No specific preventive or curative strategies currently exist for pneumonia-induced lung failure.
- Adjuvant therapies are being explored for pneumonia, sepsis, and ARDS.
Conclusions:
- Targeting innate immune dysregulation is crucial for treating severe pneumonia.
- Further research is needed to translate preclinical findings into clinical practice.
- Adjuvant therapies hold potential for improving outcomes in pneumonia and its severe complications.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
07:43A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
Published on: September 28, 2016
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
Atypical Pneumonia
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pneumonia II: Pathophysiology